SOUTH SAN FRANCISCO, Calif., Sept. 26, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the initiation of a Phase 1 clinical study of MLN2480, an oral, investigative drug selective for pan-Raf kinase inhibition, that is being studied in patients with relapsed or refractory solid tumors. The study is sponsored by Millennium Pharmaceuticals, Inc., which is developing MLN2480 in oncology in collaboration with Sunesis. Under their agreement, Sunesis is eligible to receive milestone payments and royalties on sales of future collaboration products and retains future co-development and co-promotion rights.
